RASEGLURANT
Raseglurant is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | RASEGLURANT |
| INN | raseglurant |
| Description | Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.
|
| Classification | Small molecule |
| Drug class | metabotropic glutamate receptor antagonists, negative allosteric modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 757950-09-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545036 |
| ChEBI ID | — |
| PubChem CID | 10331863 |
| DrugBank | — |
| UNII ID | 66UCJ8Z8L1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use